@article {369,
	title = {Drug Review: Terlipressin},
	journal = {International Journal of Pharmacology and Clinical Sciences},
	volume = {12},
	year = {2023},
	month = {February 2024},
	pages = {138-139},
	type = {Research Article},
	chapter = {138},
	abstract = {<p class="rtejustify">Registrations: It had been registered in the following countries: United Kingdom (UK), United States of America (USA), Canada, and Saudi Arabia (SA). Trade name (USA.); TERLIVAZ {\textregistered} Registration number (SA); 11-367-07. Insurance Drug Formulary (SA); Covered. General Information: Registered Company: Mallinckrodt hospital products inc. Regulatory Status: RX. Mechanism of Action: Prodrug The active form is lysine vasopressin, the non-selective agonist of both V1 (smooth muscles of the arterial vasculature in the splanchnic region) and V2 receptors (collecting ducts of renal tubules). <strong>Read more...</strong></p>
},
	doi = {10.5530/ijpcs.2023.12.17},
	author = {Juman Alsaab}
}
